Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00542022 | Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008) | PHASE2 | COMPLETED | 149 | — | — | Jun 1, 2004 | May 1, 2005 | Oct 20, 2015 | - | — |
| Name | Type | Description |
|---|---|---|
| MK0812 / Duration of Treatment: 12 Weeks | DRUG | - |
| Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks | DRUG | - |
Inclusion Criteria: * Patient has had diagnosis of RA made at least 6 months prior to study start and was greater than 16 years of age when diagnosed * Patient has active RA with a minimum level of disease activity including at least 10 swollen joints and 10 tender or painful joints * Excepting rhe...